Globus Medical’s transaction will include all shares of Nevro, which are valued at about $250 million. The deal is slated to close in the second quarter.
“We believe our size and operational capabilities will accelerate market penetration of Nevro’s technology and bring much needed and clinically superior relief to patients suffering from chronic pain,” Globus Medical CEO Dan Scavilla, said in the release. “In addition, our scale and operational discipline will allow us to optimize Nevro’s financial performance to drive enhanced profitability and create long-term value moving ahead.”
Nevro uses HFX spinal cord stimulation, which is used in its Senza SCS system. The company also has minimally invasive treatments for chronic sacroiliac joint pain.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
